All articles by RanjithKumar Dharma

RanjithKumar Dharma

Hopewell Therapeutics raises funds for genomic medicines development

The funds will support the development of genomic medicines, using the company’s differentiated ttLNP platform.

China’s NMPA approves Vascepa for hypertriglyceridemia

Amarin will secure a regulatory milestone payment of $5m, as a result of the NMPA approval.

Janssen submits NDA to FDA for PAH combination therapy

The NDA was submitted based on positive data from the Phase III A DUE study.

Stealth and Pharmanovia partner for commercialisation of elamipretide

Pharmanovia will focus on commercialising elamipretide in Europe and other key global territories.

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

Betta will develop, produce and commercialise CFT8919 in the licensed territories.

XtalPi announces $250m AI drug discovery collaboration with Eli Lilly

XtalPi brings together AI “dry lab” algorithms and “wet lab” robotics to drive innovation.

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

SKYCovion was created in collaboration with GSK’s pandemic adjuvant and is suitable for storage between 2° and 8° Celsius.

Valneva seeks Health Canada approval for chikungunya vaccine

The single-shot vaccine is intended for persons aged 18 years and above.

Roche Canada and pCPA conclude talks for Vabysmo eye therapy

Vabysmo helps treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular oedema (DME).

Sun Pharma and Philogen sign licence agreement for anti-cancer therapy

Sun Pharma will commercialise Nidlegy in three countries to treat skin cancers.